Study of Nesiritide in Diastolic Heart Failure.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00309868|
Recruitment Status : Completed
First Posted : April 3, 2006
Last Update Posted : March 26, 2014
|Condition or disease||Intervention/treatment||Phase|
|Diastolic Heart Failure||Drug: neseritide||Phase 1 Phase 2|
In previous studies, patients with systolic heart failure were given nesiritide and had reduced heart filling pressures. The FDA has approved nesiritide for these patients.
Between one-third and one-half of patients with heart failure have diastolic heart failure. Few of these patients have been studied while receiving nesiritide.
A study is needed to test nesiritide on this specific type of heart failure.
Patients will undergo a heart catheterization and heart biopsy. Patients will then be transferred to the intensive care unit for monitoring. An echocardiogram will be obtained, followed by an infusion of nesiritide for 24 hours. At the completion of the infusion, a repeat echocardiogram will be obtained.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Study of the Acute Hemodynamic and Myocardial Effects of Nesiritide in Diastolic Heart Failure.|
|Study Start Date :||December 2002|
|Actual Primary Completion Date :||December 2003|
|Actual Study Completion Date :||December 2003|
- Drug: neseritide
Other Name: BNP
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00309868
|Principal Investigator:||Marc J S, MD||Massachusetts General Hospital|